Atsena Therapeutics at ESGCT 2026

Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website

Atsena Therapeutics brings 2 presentations to ESGCT 2026 in Hamburg. Its work centres on AAV gene therapy for inherited retinal disease using a capsid that spreads laterally under the retina. Topics include dual-vector delivery of the large MYO7A gene for Usher syndrome type 1B and reaching the macula from a peripheral injection.

OrganizationESGCT 2026 Attendance
Atsena Therapeutics
Durham, North Carolina
atsenatx.com
Biotech
Clinical-stage developer of AAV gene therapies for inherited retinal diseases, including programs built on its laterally spreading AAV.SPR capsid.
Poster
Wed Oct 28
1:30pm–3:30pm
An optimized dual AAV.SPR platform for MYO7A delivery supports clinical development for Usher Syndrome Type 1B
AAVs / non integrative vectors
Poster
Wed Oct 28
1:30pm–3:30pm
Laterally spreading AAV.SPR enables safe and efficient RS1 delivery to the macula after peripheral subretinal injection
AAVs / non integrative vectors

Explore the full ESGCT 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Hamburg. Leave your work email and we’ll be in touch.

Privacy

Download the full ESGCT 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Atsena Therapeutics

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction